Company Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).
The company is also developing Entinostat.
It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
| Country | United States |
| IPO Date | Mar 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Michael A. Metzger M.B.A. |
Contact Details
Address: 35 Gatehouse Drive Waltham, Massachusetts United States | |
| Website | https://www.syndax.com |
Stock Details
| Ticker Symbol | SNDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001395937 |
| CUSIP Number | 87164F105 |
| ISIN Number | US87164F1057 |
| Employer ID | 32-0162505 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Metzger M.B.A. | Chief Executive Officer & Director |
| Keith Alan Goldan CPA | Chief Financial Officer, Treasurer & Chief Accounting Officer |
| Dr. Catherine Madigan M.D. | Chief Medical Officer |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Dr. Neil Gallagher M.D., Ph.D. | President, Head of Research & Development |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Luke J. Albrecht J.D. | Senior Vice President, General Counsel & Secretary |
| Sharon Klahre | Vice President of Investor Relations & Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 05, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |